Web Research
Web Research — Centene Corporation (CNC)
The Bottom Line from the Web
The single biggest signal the internet adds beyond the filings: on July 1, 2025, Centene withdrew 2025 guidance after independent actuary (Wakely) data revealed an unexpected $1.8B Marketplace risk-adjustment shortfall across 22 states (72% of CNC's exchange book), erasing >$11B of market cap in one trading session (–40%) and triggering an active securities class action (Lunstrum v. Centene, S.D.N.Y. 25-cv-05659). Q1 2026 then printed a $3.37 adjusted EPS beat vs ~$2.15 consensus, and management raised 2026 adjusted EPS guidance to >$3.40 — but the credibility scar from a 62% miss vs initial $7.25+ EPS still anchors a Hold consensus and a sub-investment-grade credit profile (S&P BB+, Fitch BBB-/Negative).
The web reframes CNC from "stable Medicaid leader" (filings narrative through 2024) into a turnaround with active class-action overhang, a director defection to UnitedHealth, and a House Judiciary subpoena on ACA subsidy fraud — all on top of the multi-state Envolve PBM settlements ($1.96B cumulative penalties tracked by Good Jobs First).
What Matters Most
1. July 2025 guidance pull and the $11B one-day wipeout
CNC withdrew full-year 2025 guidance on July 1, 2025. Wakely actuarial data showed risk-pool morbidity in 22 states materially worse than the company had reserved for; the implied EPS hit was roughly –$2.75 vs prior ≥$7.25 guidance. Stock fell ~40% in extended trading; >$11B market cap destroyed in one day. Source: Reuters, Investopedia, PRNewswire/Hagens Berman.
Red flag. Magnitude (62% EPS miss) implies the prior reserving model materially understated marketplace acuity. Lead plaintiff deadline was September 8, 2025; Lunstrum class action active in S.D.N.Y.
2. Q1 2026 beat and guidance raise — fragile but real
Q1 2026 adjusted EPS $3.37 vs ~$2.15 consensus (+57%). Revenue $49.94B vs $47.04B est. Medicaid HBR fell to 93.1% (from >94%), Medicare HBR 84.9%, Commercial 75.3%. FY26 adjusted EPS guide raised from >$3.00 to >$3.40; revenue raised ~$1B to ~$189.5B. Source: Reuters, Seeking Alpha, Fool transcript.
Positive. Five analysts upgraded post-print: BofA Underperform→Buy ($34→$60), Cantor $38→$60, Barclays $35→$63, TD Cowen $38→$47. June 2026 Wakely refresh is the next checkpoint for Marketplace risk-adjustment receivable.
3. OBBBA Medicaid work-requirement law — biggest 2026-27 overhang
The "One Big Beautiful Bill" (OBBBA) signed July 4, 2025 mandates work requirements for non-disabled Medicaid adults; phased state rollout 2026-2027. ~57% of CNC revenue ties to Medicaid (~12.5M lives across ~30 states). State rate offsets unconfirmed; analyst views range from 5-10% membership attrition risk to material margin compression if rate updates lag. Source: tikr, Morningstar.
Watch. This is the variable nobody — including management — has fully scoped. OBBBA implementation trumps short-term HBR data.
4. ACA marketplace membership cliff: 5.6M → 3.6M in 12 months
Marketplace membership fell ~2.0M (≈36%) Q1 2025 → Q1 2026 after enhanced APTC subsidies expired. CNC repriced 2026 plans aggressively (claims 95% morbidity coverage); whether that's enough is the central H2 2026 question. Source: FierceHealthcare.
5. CMS 2027 Medicare Advantage rates +2.48% — favorable surprise
CMS finalized 2027 MA rates at +2.48% average payment, well above the ~0.09% earlier proposal. Industry tailwind worth ~$13B+ in revenue. Supports CNC's stated path to MA breakeven by 2027 (1.0M MA members, high D-SNP mix). Source: AAMC summary.
6. Director Wayne DeVeydt jumps from CNC board to UnitedHealth CFO (Aug 2025)
Centene director (added 2021 in the Politan settlement) departed in August 2025 to become UnitedHealth's CFO — the direct competitor with the strongest vertical-integration moat. Optics: insider with full visibility into CNC's reset chose UNH over staying. Source: St. Louis Business Journal.
Governance signal. During an active reset and class-action period, a board member departing to the dominant competitor is non-trivial. Not insider trading, but a credibility data point.
7. Credit downgrades — Centene now sub-IG at S&P
S&P cut to BB+ (below investment grade) in 2025; Fitch affirmed BBB- but moved outlook to Negative Sept 16, 2025; Moody's Ba1 stable. $2.5B due Dec 2027 + $3.5B due Dec 2029 + $2.0B due Feb 2030 — refinancing window opens 2026-27 at speculative-grade spreads. Source: S&P, Fitch entity page, TipRanks credit agreement.
8. House Judiciary subpoena on ACA subsidy fraud (Feb 2026)
House Judiciary Committee Republicans subpoenaed eight ACA insurers — Centene included — in February 2026 for documents on alleged Obamacare subsidy / enrollment-manipulation fraud. Outcome unknown; political risk to Marketplace and Medicaid book. Source: Reuters company page.
9. Envolve PBM settlements — pattern, not one-off
Cumulative state Medicaid PBM-overbilling settlements include Ohio $88.3M (Jun 2021), Mississippi $55.7M (2021), Washington $33.3M (Aug 2022), Indiana $66.5M (2023), Iowa $44.4M (2022), California $215M (Feb 2023). Good Jobs First Violation Tracker totals ~$1.96B in penalties since 2000. Source: Cohen Milstein, Reuters Ohio/MS, Reuters Washington, Violation Tracker.
10. Goodwill impairment $6.7B in Q3 2025; Magellan Specialty divested Dec 2025
Q3 2025 carried a $6.7B noncash goodwill impairment tied to Marketplace valuation reset; no impact on adjusted EPS or covenants (debt-to-cap 45.5%, well below 60%). Magellan Specialty divested December 2025 generating $513M pre-tax loss but simplifying the portfolio. Source: Fool Q3 2025 transcript, Centene IR Feb 6 2026 results.
Recent News Timeline
What the Specialists Asked
Governance and People Signals
Executive snapshot
Settlement / litigation history
Pattern read. Six discrete state Medicaid PBM settlements, plus House Judiciary subpoena (Feb 2026), plus active securities class action — Centene faces persistent regulatory and enforcement attention rather than a single isolated incident.
Insider / ownership signals
Institutional ownership ~96.5%; insider ~3.7%. Past 24 months: insiders bought ~73,240 shares for ~$3.4M (no headline-size sales). Largest individual holder remains the late Michael Neidorff estate at ~7.18M shares (~1.46%). Most material governance event: director Wayne DeVeydt → UnitedHealth CFO (Aug 4, 2025).
Industry Context
The web reveals three structural shifts the filings only hint at:
- Vertical integration is winning. UnitedHealth's Optum stack (PBM + provider + data) is consistently cited as 5-10% medical-cost advantage. CNC just unwound Magellan and has no equivalent.
- Government-program exposure is now a policy variable, not a moat. OBBBA work requirements + APTC sunset + House Judiciary scrutiny mean CNC's "government-sponsored" niche carries political beta that wasn't priced pre-2025.
- Execution divergence inside the peer set. Molina stayed profitable through the same 2025 risk-pool reset that crushed CNC — undermining the "industry-wide" excuse and reframing CNC's miss as a pricing/selection error.
Net. The thesis investors get from filings — "scaled Medicaid leader, recovering margins, $3.40+ EPS in 2026" — survives the web. The thesis investors don't get from filings — class-action overhang, sub-IG credit, OBBBA tail, director defection to UNH, recurring PBM enforcement — is what changes the entry decision.